

SUPPLEMENTARY MATERIALS

Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden

Shirley P Huang, PharmD, MS; Maral DerSarkissian, PhD; Yuqian M Gu, MS; Mei Sheng Duh, MPH, ScD; Min-Jung Wang, ScD, MS; John Benson, BA; Jensen Vu, BA; Carlyne Averell, MS, SM; Christopher F Bell, PharmD

SUPPLEMENTARY MATERIAL Included OCS therapies

SUPPLEMENTARY TABLE 1 ICD-9-CM and ICD-10-CM codes used for baseline comorbidities

SUPPLEMENTARY TABLE 2 12-Month disease severity and flare occurrence (N=37,726)

SUPPLEMENTARY TABLE 3 Health care costs for the prevalent OCS use cohort (>7.5 mg/day) exposure categories and the no OCS use cohort, over the 12-month observation period (N=37,725)

SUPPLEMENTARY TABLE 4 Odds of experiencing OCS-related AEs by organ domain in the prevalent OCS use cohort exposure categories and the no OCS use cohort over the observation period (N=37,725)

SUPPLEMENTARY FIGURE 1 Study attrition

SUPPLEMENTARY FIGURE 2 OCS ADD by observation period and days supply definitions (N=16,209)

Supplementary Material

Included OCS therapies

OCS therapies included oral formulations of:

Betamethasone

Budesonide

Cortisone

Deflazacort

Dexamethasone

Fludrocortisone

Hydrocortisone

Methylprednisolone

Prednisolone

Prednisone

Triamcinolone

Supplementary Table 1. ICD-9-CM and ICD-10-CM codes used for baseline comorbidities

Category	Condition	ICD-9-CM Code(s)	Description	ICD-10-CM Code(s)	Description
Infections	Fungal infections	110.xx	Dermatophytosis	B35.x	Dermatophytosis
		111.xx	Dermatomyces other and unspecified	B36.x	Other superficial mycoses
		112.xx	Candidiasis	B37.x	Candidiasis
		117.xx	Other mycoses	B48.x B49	Other mycoses, not elsewhere classified Unspecified mycosis
		118	Opportunistic mycoses	B48.8	Other specified mycoses
		202.1x	Mycosis fungoides	C84.0x	Mycosis fungoides
		370.05	Mycotic corneal ulcer	H16.061 H16.062 H16.063 H16.069	Mycotic corneal ulcer, right eye H16.062 Mycotic corneal ulcer, left eye H16.063 Mycotic corneal ulcer, bilateral Mycotic corneal ulcer, unspecified eye
		484.7	Pneumonia in other systemic mycoses	J17	Pneumonia in diseases classified elsewhere
		V75.4	Screening examination for mycotic infections	Z11.8	Encounter for screening for other infectious and parasitic diseases
		Pneumonia	003.22	Salmonella pneumonia	A02.22
	011.6x		Tuberculous pneumonia	A15.0	Tuberculosis of lung
	020.5x		Pneumonic plague, unspecified	A20.2	Pneumonic plague
	055.1x		Postmeasles pneumonia	B05.2	Measles complicated by pneumonia
	073.0x		Ornithosis with pneumonia	A70 and J17	Chlamydia psittaci infections AND Pneumonia in diseases classified elsewhere

		112.4x	Candidiasis of lung	B37.1	Pulmonary candidiasis
		115.15	Infection by <i>Histoplasma duboisii</i> , pneumonia	B39.5 and J17	<i>Histoplasmosis duboisii</i> AND Pneumonia in diseases classified elsewhere
		115.95	Histoplasmosis, unspecified, pneumonia	B39.9 and J17	Histoplasmosis, unspecified AND Pneumonia in diseases classified elsewhere
		136.3x	Pneumocystosis	B59	Pneumocystosis
		466.1x	Acute bronchiolitis	J21.x	Acute bronchiolitis
		480.xx	Viral pneumonia	J12.x	Viral pneumonia, not elsewhere classified
		481.xx	Pneumococcal pneumonia [<i>Streptococcus pneumoniae</i> pneumonia]	J13 J18.1	Pneumonia due to <i>Streptococcus pneumoniae</i> Lobar pneumonia, unspecified organism
		482.xx	Other bacterial pneumonia	J15.x	Bacterial pneumonia, not elsewhere classified
		483.xx	Pneumonia due to other specified organism	J15.7 J16.0 J16.8	Pneumonia due to <i>Mycoplasma pneumoniae</i> Chlamydial pneumonia Pneumonia due to other specified infectious organisms
		484.xx	Pneumonia in infectious diseases classified elsewhere	B25.0 A37.01 A37.11 A37.81 A37.91	Cytomegaloviral pneumonitis Whooping cough due to <i>Bordetella pertussis</i> with pneumonia Whooping cough due to <i>Bordetella parapertussis</i> with pneumonia Whooping cough due to other <i>Bordetella</i> species with pneumonia Whooping cough, unspecified species with pneumonia

			A22.1 B44.0 J17	Pulmonary anthrax Invasive pulmonary aspergillosis Pneumonia in diseases classified elsewhere
		485.xx	Bronchopneumonia, organism unspecified	J18.0 Bronchopneumonia, unspecified organism
		486.xx	Pneumonia, organism unspecified	J18.8 Other pneumonia, unspecified organism J18.9 Pneumonia, unspecified organism
		487.0x	Influenza with pneumonia	J10.0x Influenza due to other identified influenza virus with pneumonia J11.0x Influenza due to unidentified influenza virus with pneumonia J12.9 Viral pneumonia, unspecified
		488.01	Influenza due to identified avian influenza virus with pneumonia	J09.X1 Influenza due to identified novel influenza A virus with pneumonia
		488.11	Influenza due to identified 2009 h1n1 influenza virus with pneumonia	J10.08 Influenza due to other identified influenza virus with other specified pneumonia
		514	Pulmonary congestion and hypostasis	J18.2 Hypostatic pneumonia, unspecified organism J81.1 Chronic pulmonary edema
		516.8	Other specified alveolar and parietoalveolar pneumonopathies	J84.09 Other alveolar and parieto-alveolar conditions
		517.1x	Rheumatic pneumonia	J17 Pneumonia in diseases classified elsewhere

		518.3x	Pulmonary eosinophilia	J82	Pulmonary eosinophilia, not elsewhere classified
		V12.61	Personal history of pneumonia (recurrent)	Z87.01	Personal history of pneumonia (recurrent)
		V73.9x	Screening examination for unspecified viral and chlamydial disease	Z11.8 Z11.59	Encounter for screening for other infectious and parasitic diseases Encounter for screening for other viral diseases
	Tuberculosis	010.xx-018.xx	Tuberculosis	A15.xx- A19.xx	Tuberculosis
		795.5x	Nonspecific reaction to test for tuberculosis	R76.11 R76.12	Nonspecific reaction to tuberculin skin test without active tuberculosis Nonspecific reaction to cell mediated immunity measurement of gamma interferon antigen response without active tuberculosis
		V01.1	Contact with or exposure to tuberculosis	Z20.1	Contact with and (suspected) exposure to tuberculosis
		V03.2	Need for prophylactic vaccination and inoculation against tuberculosis	Z23	Encounter for immunization
		V71.2	Observation for suspected tuberculosis	Z03.89	Encounter for observation for other suspected diseases and conditions ruled out
		V74.1	Screening examination for pulmonary tuberculosis	Z11.1	Encounter for screening for respiratory tuberculosis
		599.0x	Chronic pyelonephritis	N39.0	Urinary tract infection, site not specified

	Urinary tract infection	997.5x	Urinary complications, not elsewhere classified	N99.0 N99.52x N99.53x N99.81 N99.89	Postprocedural (acute) (chronic) kidney failure Complication of incontinent external stoma of urinary tract Complication of continent stoma of urinary tract Other intraoperative complications of genitourinary system Other postprocedural complications and disorders of genitourinary system
	Varicella infection	052.xx	Chickenpox	B01.x	Varicella [chickenpox]
		053.xx	Herpes zoster	B02.xx	Zoster [herpes zoster]
		V05.4	Need for prophylactic vaccination and inoculation against varicella	Z23	Encounter for immunization
		V01.71	Contact with or exposure to varicella	Z20.820	Contact with and (suspected) exposure to varicella
	Sepsis	038.xx	Septicemia	A40.x	Streptococcal sepsis
		670.2x	Puerperal sepsis	085	Puerperal sepsis
		995.91	Sepsis	A41.x	Other sepsis
				A42.7	Actinomycotic sepsis
				A54.86	Gonococcal sepsis
995.92	Severe sepsis	B37.7	Candidal sepsis		
		R65.20	Severe sepsis without septic shock		
			R65.21	Severe sepsis with septic shock	

Osteoporosis	Osteoporosis	733.0x	Osteoporosis	M80.x	Osteoporosis with current pathological fracture			
				M81.x	Osteoporosis without current pathological fracture			
Cardiovascular diseases	Myocardial infarction	410.xx	Acute myocardial infarction	I21.x	Acute myocardial infarction			
				I22.x	Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction			
		412.xx	Old myocardial infarction	I25.2	Old myocardial infarction			
	Congestive heart failure	398.91 402.01 402.11 402.91	Rheumatic heart failure (congestive) Malignant hypertensive heart disease with heart failure Benign hypertensive heart disease with heart failure Unspecified hypertensive heart disease with heart failure	I09.9	Rheumatic heart disease, unspecified			
					404.01 404.03 404.11 404.13 404.91 404.93	Hypertensive heart and chronic kidney disease	I11.0	Hypertensive heart disease with heart failure
					I13.0		Hypertensive heart and chronic kidney disease	
					I13.2			

		425.4- 425.9	Other primary cardiomyopathies Alcoholic cardiomyopathy Nutritional and metabolic cardiomyopathy Cardiomyopathy in other diseases classified elsewhere Secondary cardiomyopathy, unspecified	I25.5 I42.0 I42.5 I42.6 I42.7 I42.8 I42.9 I43	Ischemic cardiomyopathy Dilated cardiomyopathy Other restrictive cardiomyopathy Alcoholic cardiomyopathy Cardiomyopathy due to drug and external agent Other cardiomyopathies Cardiomyopathy, unspecified Cardiomyopathy in diseases classified elsewhere
		428.x	Heart failure	I50.x P29.0	Heart failure Neonatal cardiac failure
	Hypertension	401.xx- 405.xx	Hypertensive diseases	I10.x-I16.x	Hypertensive diseases
	Cerebrovascular disease	430.x- 438.x 362.34	Cerebrovascular disease Transient retinal arterial occlusion	G45.x G46.x H34.0x I60.x-I69.x	Transient cerebral ischemic attacks and related syndromes Vascular syndromes of brain in cerebrovascular diseases Transient retinal artery occlusion Cerebrovascular diseases

	Peripheral vascular disease	093.0 437.3 440.x 441.x 447.1 557.1 557.9 443.1- 443.9 V43.4	Aneurysm of aorta, specified as syphilitic Cerebral aneurysm, nonruptured Atherosclerosis Aortic aneurysm and dissection Stricture of artery Chronic vascular insufficiency of intestine Unspecified vascular insufficiency of intestine Other peripheral vascular disease Blood vessel replaced by other means	I70.x I71.x I73.1 I73.8x I73.9 I77.1 I79.0 I79.2 K55.1 K55.8 K55.9 Z95.8 Z95.9	Atherosclerosis Aortic aneurysm and dissection Thromboangiitis obliterans [Buerger's disease] Other specified peripheral vascular diseases Peripheral vascular disease, unspecified Stricture of artery Aneurysm of aorta in diseases classified elsewhere Peripheral angiopathy in diseases classified elsewhere Chronic vascular disorders of intestine Other vascular disorders of intestine Vascular disorder of intestine, unspecified Presence of other cardiac and vascular implants and grafts Presence of cardiac and vascular implant and graft, unspecified
Stroke	Stroke	433.01 433.11 433.21 433.31	Occlusion and stenosis of basilar artery with cerebral infarction Occlusion and stenosis of carotid artery with cerebral infarction Occlusion and stenosis of vertebral artery with cerebral infarction Occlusion and stenosis of multiple and bilateral	I63.x	Cerebral infarction

		433.81	precerebral arteries with cerebral infarction Occlusion and stenosis of other specified precerebral artery with cerebral infarction		
		433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction		
		434.01			
		434.11	Cerebral thrombosis with cerebral infarction		
		434.91	Cerebral embolism with cerebral infarction Cerebral artery occlusion, unspecified with cerebral infarction		
Diabetes	Diabetes mellitus	250.xx	Diabetes mellitus	E08.x-E14.x	Diabetes mellitus
Renal disease	Renal disease	V42.0	Kidney replaced by transplant	N03.2-	Chronic nephritic syndrome
		V45.1x	Renal dialysis status; postprocedural state	N03.7	Unspecified nephritic syndrome
		V56.x	Encounter for dialysis and dialysis catheter care	N05.2-	
		582.x	Chronic glomerulonephritis	N05.7	Chronic kidney disease (CKD)
		585.x	Chronic kidney disease (CKD)	N18.x	Unspecified kidney failure
		586	Renal failure, unspecified	N19	Renal osteodystrophy
		588.0	Renal osteodystrophy	N25.0	Preparatory care for renal dialysis
		583.0-	Nephritis and nephropathy, not specified as acute	Z49.0x	Extracorporeal dialysis
		583.7	or chronic	Z49.1	Other dialysis
				Z49.2	Kidney transplant status
				Z94.0	Dependence on renal dialysis
				Z99.2	

		403.01 403.11 403.91 404.02 404.03 404.12 404.13 404.92 404.93	Hypertensive chronic kidney disease Hypertensive heart and chronic kidney disease	I12.0 I13.1x	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease Hypertensive heart and chronic kidney disease without heart failure
Immuno-inflammation-related	Rheumatoid arthritis	714.0 714.2	Rheumatoid arthritis Other rheumatoid arthritis with visceral or systemic involvement	M05.1x M05.2x M05.3x M05.4x M05.5x M05.7x M05.8x	Rheumatoid lung disease with rheumatoid arthritis Rheumatoid vasculitis with rheumatoid arthritis Rheumatoid heart disease with rheumatoid arthritis Rheumatoid myopathy with rheumatoid arthritis Rheumatoid polyneuropathy with rheumatoid arthritis Rheumatoid arthritis with rheumatoid factor without organ or systems involvement Other rheumatoid arthritis with rheumatoid factor Rheumatoid arthritis with rheumatoid factor,

				M05.9 M06.0x M06.2x M06.3x M06.8x M06.9	unspecified Rheumatoid arthritis without rheumatoid factor Rheumatoid bursitis Rheumatoid nodule Other specified rheumatoid arthritis Rheumatoid arthritis, unspecified
	Thyroiditis	245.x	Thyroiditis	E06.x	Thyroiditis
	Inflammatory bowel disease (IBD)	555.x 556.x	Regional enteritis Ulcerative enterocolitis	K50.x K51.x	Crohn's disease (regional enteritis) Ulcerative colitis

ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CM: International Classification of Diseases, Tenth Revision, Clinical Modification.

Supplementary Table 2. 12-month disease severity and flare occurrence (N=37,726)

	No OCS use (n=21,517)	0 periods of prevalent OCS use (n=5,390)	1 period of prevalent OCS use (n=4,491)	2 periods of prevalent OCS use (n=6,328)
Disease severity, n (%)				
Mild	15,970 (74.2)	1,401 (26.0) ^a	346 (7.7) ^a	158 (2.5) ^a
Moderate	3,632 (16.9)	3,170 (58.8) ^a	3,017 (67.2) ^a	4,191 (66.2) ^a
Severe	1,915 (8.9)	819 (15.2) ^a	1,128 (25.1) ^a	1,979 (31.3) ^a
SLE flares				
Patients with ≥1 SLE flare, n (%)	13,085 (60.8)	4,807 (89.2) ^a	4,227 (94.1) ^a	6,008 (94.9) ^a
Number of any SLE flares per patient, mean (SD)	1.9 (1.0)	2.8 (1.3) ^a	3.1 (1.4) ^a	3.1 (1.5) ^a
Patients with ≥1 mild SLE flare, n (%)	4,072 (18.9)	2,378 (44.1) ^a	2,129 (47.4) ^a	2,769 (43.8) ^a
Number of mild SLE flares per patient, mean (SD)	1.3 (0.5)	1.4 (0.7) ^a	1.3 (0.6) ^a	1.3 (0.6) ^a
Patients with ≥1 moderate SLE flare, n (%)	11,172 (51.9)	4,309 (79.9) ^a	3,932 (87.6) ^a	5,624 (88.9) ^a
Number of moderate SLE flares per patient, mean (SD)	1.7 (0.8)	2.2 (1.1) ^a	2.3 (1.1) ^a	2.3 (1.1) ^a
Patients with ≥1 severe SLE flare, n (%)	546 (2.5)	385 (7.1) ^a	775 (17.3) ^a	1,527 (24.1) ^a
Number of severe SLE flares per patient, mean (SD)	1.2 (0.7)	1.3 (0.7) ^b	1.3 (0.6) ^c	1.4 (0.9) ^a

Patients with ≥ 1 moderate/severe SLE flare, n (%)	11,352 (52.8)	4,374 (81.2) ^a	4,016 (89.4) ^a	5,753 (90.9) ^a
Number of moderate/severe SLE flares per patient, mean (SD)	1.7 (0.9)	2.3 (1.1) ^a	2.5 (1.2) ^a	2.6 (1.3) ^a

^ap<0.01 compared with the no OCS use cohort; ^bp \geq 0.05 compared with the no OCS use cohort; ^cp<0.05 compared with the no OCS use cohort
OCS, oral corticosteroids; SD, standard deviation; SLE, systemic lupus erythematosus

Supplementary Table 3. Healthcare costs for the prevalent OCS use cohort (>7.5 mg/day) exposure categories and the no OCS use cohort, over the 12-month observation period (N=37,725)

2018 USD	No OCS use (n=21,516)	0 periods of prevalent OCS use (n=8,901)	1 period of prevalent OCS use (n=3,595)	2 periods of prevalent OCS use (n=3,713)
Total costs, USD, mean (SD)	12,109 (22,821)	25,516 (39,343)	40,816 (59,349)	52,927 (76,032)
Adjusted cost difference ^a (95% CI) vs the no OCS use cohort	-	7,033 (6,187, 7,907)	16,231 (14,438, 18,184)	23,020 (20,632, 25,305)
Medical costs, mean (SD)	9612 (20,675)	18,955 (35,283)	32,172 (54,423)	41,180 (68,504)
Adjusted cost difference ^a (95% CI) vs the no OCS use cohort	-	4818 (4,048, 5,622)	13,319 (11,582, 15,275)	18,777 (16,562, 21,062)
Pharmacy costs, mean (SD)	2226 (4899)	6,121 (9,059)	8,174 (12,004)	11,016 (17,063)
Adjusted cost difference ^a (95% CI) vs the no OCS use cohort	-	2,084 (1,842, 2,314)	2,895 (2,545, 3,248)	3,999 (3,578, 4,435)

^ap<0.01

CI, confidence intervals; OCS, oral corticosteroids; SD, standard deviation; USD, United States Dollars

Supplementary Table 4. Odds of experiencing OCS-related AEs by organ domain in the prevalent OCS use cohort exposure categories and the no OCS use cohort over the observation period (N=37,725)

	No OCS use (n=21,516)	0 periods of OCS use (n=5,390)	1 period of OCS use (n=4,491)	2 periods of OCS use (n=6,328)
Any OCS-related AE				
<i>Incidence, %</i>	75.3	85.7	89.3	91.9
<i>Adjusted OR (95% CI)</i>	-	1.39 (1.25, 1.55)	1.80 (1.57, 2.06)	2.32 (2.02, 2.68)
<i>P-value</i>	-	<0.01	<0.01	<0.01
Bone and muscle^a				
<i>Incidence, %</i>	26.1	36.9	41.3	45.8
<i>Adjusted OR (95% CI)</i>	-	1.46 (1.35, 1.59)	1.69 (1.54, 1.85)	1.92 (1.75, 2.10)
<i>P-value</i>	-	<0.01	<0.01	<0.01
Immune system-related^b				
<i>Incidence, %</i>	20.4	31.1	37.0	43.3
<i>Adjusted OR (95% CI)</i>	-	1.40 (1.29, 1.52)	1.65 (1.51, 1.81)	2.02 (1.85, 2.21)
<i>P-value</i>	-	<0.01	<0.01	<0.01
Central nervous system^c				
<i>Incidence, %</i>	27.6	32.5	36.3	39.3
<i>Adjusted OR (95% CI)</i>	-	1.11 (1.02, 1.21)	1.23 (1.11, 1.36)	1.38 (1.25, 1.52)
<i>P-value</i>	-	0.02	<0.01	<0.01
Metabolic and endocrine^d				
<i>Incidence, %</i>	32.8	34.0	37.4	42.1
<i>Adjusted OR (95% CI)</i>	-	0.97 (0.89, 1.06)	1.04 (0.94, 1.15)	1.22 (1.11, 1.35)
<i>P-value</i>	-	0.46	0.46	<0.01
Cardiovascular^e				
<i>Incidence, %</i>	36.6	45.7	49.9	55.7
<i>Adjusted OR (95% CI)</i>	-	1.32 (1.21, 1.45)	1.53 (1.37, 1.70)	1.95 (1.76, 2.17)
<i>P-value</i>	-	<0.01	<0.01	<0.01
Gastrointestinal^f				
<i>Incidence, %</i>	11.1	16.9	20.3	25.4
<i>Adjusted OR (95% CI)</i>	-	1.36 (1.23, 1.51)	1.46 (1.31, 1.63)	1.90 (1.71, 2.11)
<i>P-value</i>	-	<0.01	<0.01	<0.01
Ophthalmologic^g				
<i>Incidence, %</i>	12.5	13.8	16.2	17.0
<i>Adjusted OR (95% CI)</i>	-	1.04 (0.92, 1.16)	1.37 (1.21, 1.56)	1.41 (1.25, 1.60)

<i>P-value</i>	-	0.55	<0.01	<0.01
Dermatologic ^h				
<i>Incidence, %</i>	3.1	3.0	3.2	3.8
<i>Adjusted OR (95% CI)</i>	-	0.88 (0.70, 1.09)	0.88 (0.69, 1.13)	1.06 (0.83, 1.34)
<i>P-value</i>	-	0.24	0.32	0.65
Hematologic/oncologic ⁱ				
<i>Incidence, %</i>	1.8	2.9	4.3	6.4
<i>Adjusted OR (95% CI)</i>	-	1.32 (1.06, 1.64)	1.78 (1.43, 2.22)	2.53 (2.05, 3.11)
<i>P-value</i>	-	0.01	<0.01	<0.01

^aBone and muscle disorders included bursitis, fractures, avascular necrosis, muscle weakness, loss of muscle mass, osteoporosis, back pain, and myopathy

^bImmune system-related disorders included fungal infections, pneumonia, sepsis, tuberculosis, urinary tract infection, and varicella infection

^cCentral nervous system disorders included akathisia, bipolar disorder, depression, sleep disturbances, steroid psychosis, and migraines

^dMetabolic and endocrine disorders included Cushing syndrome, diabetes mellitus, drug-induced adrenocortical insufficiency, dyslipidemia, hyperglycemia, metabolic syndrome, and obesity

^eCardiovascular disorders included atrial fibrillation/flutter, congestive heart failure, hypertension, myocardial infarction, and stroke

^fGastrointestinal disorders included abdominal distension, acute pancreatitis, chronic gastrointestinal bleeds/ulcers, dyspepsia, gastrointestinal bleeds/ulcers, and nausea/vomiting


^gOphthalmologic disorders included cataracts and glaucoma

^hDermatologic disorders included acne, erythema, and hirsutism

ⁱHematologic/oncologic disorders included bladder cancer, epistaxis, and leukocytosis

AE, adverse event; CI, confidence intervals; OCS, oral corticosteroids; OR, odds ratio; SD, standard deviation

Supplementary Figure 1. Study attrition



^aPatients with SLE were identified using International Classification of Diseases, Ninth and Tenth Revision, (ICD-9 codes and ICD-10) codes. ICD-9 codes included: 710.0x. ICD-10 codes included: M32.0, M32.1x, M32.8, and M32.9

^bPharmacy OCS claims were identified using GPI class 22, and OCS administered in a hospital or other institutional settings were identified using HCPCS codes

^cFor patients with a pharmacy claim for an OCS, a valid claim was defined as a claim with no missing values for both days of supply and quantity; 5,872 (1.5%) patients were excluded due to invalid pharmacy claims for an OCS


^dA period of continuous OCS use was defined as a period with no gaps in supply of >30 days

^eThe index date for patients was defined as the date of the first pharmacy claim for an OCS after 6-month of continuous OCS use

^fThe index date for patients without any claims for an OCS was imputed based on the distribution of time between the first SLE diagnosis within the continuous eligibility period and index date in the cohort of patients with at least one claim for an OCS

GPI, Generic product identifier; HCPCS, Healthcare Common Procedure Coding System; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; OCS, Oral corticosteroid; SLE, Systemic lupus erythematosus

Supplementary Figure 2. OCS ADD by observation period and days supply definitions (N=16,209)



ADD (observation period) was defined as total dose (strength x quantity) within each 6-month period divided by the total number of days within each 6-month period. ADD (days supply) was defined as total dose (strength x quantity) within each 6-month period divided by the total number of days of supply within each 6-month period

ADD, average daily dose; OCS, oral corticosteroid; SD, standard deviation